Recombinant Humanized (from mouse) antibody to Human IL13. Anrukinzumab (IMA-638) is a humanized monoclonal antibody designed for the treatment of asthma.
Figure 1 Visual predictive check for the final model stratified by dose.
Examples included is 200 mg i.v. (study 5, UC patients).
Hua, F., Ribbing, J., Reinisch, W., Cataldi, F., & Martin, S. (2015). A pharmacokinetic comparison of anrukinzumab, an anti‐IL‐13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients. British journal of clinical pharmacology, 80(1), 101-109.
Figure 2 Concentration vs. time profiles of anrukinzumab given as multiple i.v. 200 mg doses to UC patients or non-UC subjects.
Hua, F., Ribbing, J., Reinisch, W., Cataldi, F., & Martin, S. (2015). A pharmacokinetic comparison of anrukinzumab, an anti‐IL‐13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients. British journal of clinical pharmacology, 80(1), 101-109.
Figure 3 Effect of anrukinzumab compared with placebo on fold change in faecal calprotectin.
Reinisch, W., Panés, J., Khurana, S., Toth, G., Hua, F., Comer, G. M., ... & Zhu, H. (2015). Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut, 64(6), 894-900.
Figure 4 Median total IL-13 level versus time profile by treatment group.
Reinisch, W., Panés, J., Khurana, S., Toth, G., Hua, F., Comer, G. M., ... & Zhu, H. (2015). Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut, 64(6), 894-900.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-IL13 ADCC Recombinant Antibody (Anrukinzumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Humanized (from mouse) antibody to Human IL13. Anrukinzumab (IMA-638) is a humanized monoclonal antibody designed for the treatment of asthma.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-218 | Anti-Human IL13 Recombinant Antibody (Tralokinumab) | ELISA, FC, IP, FuncS, IF, Neut, ICC | IgG4 - lambda |
TAB-067ZJ-S(P) | Anti-Human IL-13 Recombinant Antibody scFv Fragment (CNTO 607) | ELISA, Inhib | Human antibody |
TAB-067ZJ-F(E) | Anti-Human IL-13 Recombinant Antibody Fab Fragment (CNTO 607) | ELISA, Inhib | Human antibody |
PABX-115-S (P) | Recombinant Human Anti-IL-13 Antibody scFv Fragment (C836) | WB, ELISA, FuncS | scFv |
TAB-017ML | Anti-Human IL13 Recombinant Antibody (Dectrekumab) | ELISA, IHC, FC, IP, IF, Inhib | IgG1, κ |
There are currently no Customer reviews or questions for TAB-H05. Click the button above to contact us or submit your feedback about this product.
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-H05, RRID: AB_3112022)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.